| [177Lu]Lu-RM2 | Lu-177 | — | 7 |
| [177Lu]Lu-FAPI | Lu-177 | — | 5 |
| [161Tb]Tb-DOTATATE | Tb-161 | Preclinical | 3 |
| [177Lu]Lu-DOTA-JR11 | Lu-177 | Clinical research | 3 |
| [177Lu]Lu-FAPI-04 | Lu-177 | Clinical research | 2 |
| [177Lu]Lu-FAPI-2286 | Lu-177 | — | 2 |
| [211At]At-astatobenzoate | At-211 | Clinical research | 2 |
| [177Lu]Lu-DOTA-4AH29 | Lu-177 | Preclinical | 2 |
| [90Y]Y-90-ITGA6B4 | Y-90 | — | 2 |
| [212Pb]Pb-TCMC-chOI-1 | Pb-212 | Preclinical | 2 |
| [111In]pb12 | In-111 | Preclinical | 2 |
| [177Lu]Lu-DOTA-r-a-ABA-iodoCPCR4 | Lu-177 | Preclinical | 1 |
| [177Lu]Lu-DOTA-rhCCK-18 | Lu-177 | — | 1 |
| [161Tb]Tb-3p-C-NETA | Tb-161 | Preclinical | 1 |
| [47Sc]Sc-PSMA-617 | Sc-47 | Preclinical | 1 |
| [161Tb]Tb-RM2 | Tb-161 | Preclinical | 1 |
| [212Pb]Pb-FAPI-46 | Pb-212 | — | 1 |
| [47Sc]Sc-DOTANOC | Sc-47 | Preclinical | 1 |
| [90Y]Y-90-NM600 | Y-90 | Preclinical | 1 |
| [161Tb]Tb-AMTG | Tb-161 | Preclinical | 1 |
| [225Ac]Ac-DOTA-4AH29 | Ac-225 | Preclinical | 1 |
| [177Lu]Lu-DOTA-exendin-4 | Lu-177 | Preclinical | 1 |
| [131I]I-GMIB-4AH29 | I-131 | Preclinical | 1 |
| [177Lu]Lu-satoreotide | Lu-177 | Clinical research | 1 |
| [177Lu]Lu-DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2 | Lu-177 | — | 1 |
| [188Re]Re-188-HYNIC-BBN | Re-188 | Preclinical | 1 |
| [177Lu]Lu-Rituximab | Lu-177 | Preclinical | 1 |
| [177Lu]Lu-DOTA-r-a-ABA-CPCR4 | Lu-177 | — | 1 |
| [177Lu]Lu-BL02 | Lu-177 | Preclinical | 1 |
| [131I]I-Tyr-d-peptide-PEG11-Tz | I-131 | Reported once | 1 |
| [131I]I-BNF03 | I-131 | Reported once | 1 |
| [131I]I-WS03 | I-131 | Preclinical | 1 |
| [177Lu]Lu-Comb-2 | Lu-177 | Preclinical | 1 |
| [177Lu]Lu-DOTA-ABDB6 | Lu-177 | Reported once | 1 |
| [225Ac]Ac-DOTA-MSC3 | Ac-225 | Preclinical | 1 |
| [177Lu]Lu-DOTA-KiSS-34 | Lu-177 | Preclinical | 1 |
| [177Lu]Lu-BL34 | Lu-177 | Preclinical | 1 |
| [177Lu]Lu-DOTA-11E10C11 | Lu-177 | Reported once | 1 |
| [177Lu]Lu-DOTA-GA4 | Lu-177 | Preclinical | 1 |
| [177Lu]Lu-DOTA-GA13 | Lu-177 | Reported once | 1 |
| [177Lu]Lu-PEG-Nb159 | Lu-177 | Preclinical | 1 |
| [225Ac]Ac-3p-C-DEPA-NO2 | Ac-225 | Preclinical | 1 |
| [225Ac]Ac-3p-C-DEPA-TFP-PEG4-trastuzumab | Ac-225 | Preclinical | 1 |
| [177Lu]Lu-pepa-pic2-C-Hex-KuE | Lu-177 | Reported once | 1 |
| [161Tb]Tb-pepa-pic2-C-Hex-KuE | Tb-161 | Preclinical | 1 |
| [177Lu]Lu-DOTA-iPD-L1 | Lu-177 | Preclinical | 1 |
| [177Lu]Lu-DOTA-TRK-950 | Lu-177 | Preclinical | 1 |
| [177Lu]Lu-cAC10 | Lu-177 | Preclinical | 1 |
| [177Lu]Lu-DOTA-AE105 | Lu-177 | Preclinical | 1 |
| [177Lu]Lu-LW01110 | Lu-177 | Preclinical | 1 |
| [177Lu]Lu-LW01142 | Lu-177 | Reported once | 1 |
| [177Lu]Lu-LW02060 | Lu-177 | Reported once | 1 |
| [177Lu]Lu-LW02080 | Lu-177 | Preclinical | 1 |
| [225Ac]Ac-Macropa-N4MU01 | Ac-225 | Reported once | 1 |
| [225Ac]Ac-DOTA-PKU525 | Ac-225 | Reported once | 1 |
| [131I]I-ERIC1 | I-131 | Preclinical | 1 |
| [212Pb]Pb-DOTAM-GRPR1 | Pb-212 | Preclinical | 1 |
| [177Lu]Lu-DOTA-PEG7-tetrazine | Lu-177 | Preclinical | 1 |
| [177Lu]Lu-BCY18469 | Lu-177 | Preclinical | 1 |
| [177Lu]Lu-eFAP-6 | Lu-177 | Preclinical | 1 |
| [177Lu]Lu-DOTA-POL3026 | Lu-177 | Reported once | 1 |
| [177Lu]Lu-DOTA-FD3 | Lu-177 | Reported once | 1 |
| [177Lu]Lu-PEG-(DOTA)1 | Lu-177 | Preclinical | 1 |
| [177Lu]Lu-PEG-(DOTA)1(ACUPA)3 | Lu-177 | Reported once | 1 |
| [111In]AT2S | In-111 | Preclinical | 1 |
| [177Lu]Lu-DTPA-NY003 | Lu-177 | Preclinical | 1 |
| [212Pb]Pb-eSOMA-02 | Pb-212 | Reported once | 1 |
| [177Lu]Lu-3p-C-NETA-ePSMA-16 | Lu-177 | Preclinical | 1 |
| [213Bi]Bi-3p-C-NETA-ePSMA-16 | Bi-213 | Preclinical | 1 |
| [177Lu]Lu-DOTA-MI-exendin-4 | Lu-177 | Reported once | 1 |
| [177Lu]Lu-DOTA-ABDC2 | Lu-177 | Reported once | 1 |
| [125I]NaIO3 | I-125 | Reported once | 1 |
| [211At]At-NaAtO3 | At-211 | Preclinical | 1 |
| [123I]PARPi-01 | I-123 | Preclinical | 1 |
| [111In]BQ7859 | In-111 | Reported once | 1 |
| [131I]PN67 | I-131 | Reported once | 1 |
| [131I]GV-620 | I-131 | Preclinical | 1 |
| [225Ac]Ac-hu5A10 | Ac-225 | Reported once | 1 |
| [131I]I-T-ZHP1 | I-131 | Reported once | 1 |
| [177Lu]Lu-177-AAZTA5-PSMA-617 | Lu-177 | Reported once | 1 |
| [177Lu]Lu-6R-RedFol-1 | Lu-177 | Reported once | 1 |
| [177Lu]Lu-6S-RedFol-1 | Lu-177 | Preclinical | 1 |
| [177Lu]Lu-OxFol-1 | Lu-177 | Reported once | 1 |
| [177Lu]Lu-DOTA-ST8950 | Lu-177 | Reported once | 1 |
| [131I]MEGMIB-5F7GGC | I-131 | Reported once | 1 |
| [131I]PSMA-769 | I-131 | Reported once | 1 |
| [177Lu]Lu-OncoFAP-DOTAGA | Lu-177 | Research | |
| [169Er]Er-PSMA-617 | Er-169 | Preclinical | |
| [131I]FAPI | I-131 | Preclinical | |
| [177Lu]Lu-DOTA-FAPI-04 | Lu-177 | Preclinical | |
| [188Re]Re-RC-160 | Re-188 | Preclinical | |
| [67Cu]Cu-SARTATE | Cu-67 | Preclinical | |
| [177Lu]Lu-PSMA-617-treated | Lu-177 | Clinical research | |
| [225Ac]Ac-crown-TATE | Ac-225 | — | |
| [177Lu]Lu-DOTA-NI-FAPI-04 | Lu-177 | Preclinical | |
| [211At]At-astatophenethylsuccinamate | At-211 | Preclinical | |
| [225Ac]Ac-Macropa-pertuzumab-PEG6-DM1 | Ac-225 | Preclinical | |
| [111In]DOTAGA-FAP-2286 | In-111 | Reported once | |
| [225Ac]Ac-DOTAGA-FAP-2286-ALB | Ac-225 | Reported once | |